Cannabinoid and menthol transdermal delivery systems and methods

A transdermal delivery system, comprising:

• a first hydrogel reservoir and a second hydrogel reservoir separated from each other, one of the first hydrogel reservoir and the second hydrogel reservoir including a mixture of an anionic or cationic surfactant, DMSO and a full spectrum hemp oil, and a stabilized menthol composition for lowering the rate of volatilization of menthol, the stabilized menthol composition including a pre-formed mixture consisting essentially of menthol and a menthol stabilizer compound including undecylenic acid methyl ester wherein the stabilized menthol composition is formed and encapsulated in a cyclodextrin prior to being added to the mixture of the anionic or cationic surfactant, DMSO and the full spectrum hemp oil;
• and
• a circuit apparatus including a power source, the circuit apparatus configured to supply power to the first hydrogel reservoir and the second hydrogel reservoir,
• wherein the transdermal delivery system includes less than 0.3% THC and the full spectrum hemp oil is purified to include the below stated amounts of one or more of the following impurities:
• less than 0.1 μg/kg of each of Aflatoxins BI, 82, G1, G2 and the sum of all positive Aflatoxins is less than 0.4 μg/kg;
• less than 0.1 mg/kg of each of Glufosinate, Glyphosate and Aminomethylphosphonic acid (AMPA);
• less than 0.02 mg/kg of mercury;
• less than 0.03 mg/kg of arsenic;
• less than 0.01 mg/kg of cadmium;
• and
• less than 0.05 mg/kg of lead.

A method of treating pain or inflammation in a body part or portion thereof of a mammal using a transdermal delivery system, the transdermal delivery system comprising:

• a first hydrogel reservoir and a second hydrogel reservoir separated from each other, one of the first hydrogel reservoir and the second hydrogel reservoir including a mixture of an anionic or cationic surfactant, DMSO and at least one cannabinoid, and a stabilized menthol composition for lowering the rate of volatilization of menthol, the stabilized menthol composition including a pre-formed mixture consisting essentially of menthol and a menthol stabilizer compound including undecylenic acid methyl ester wherein the stabilized menthol composition is formed and encapsulated in a cyclodextrin prior to being added to the mixture of the anionic or cationic surfactant, DMSO and the at least one cannabinoid;
• and
• a circuit apparatus including a power source, the circuit apparatus configured to supply power to the first hydrogel reservoir and the second hydrogel reservoir,
• the method comprising:
• topically applying the said first hydrogel reservoir and said second hydrogel reservoir to a skin surface of the body part of the mammal and thereby completing an electrical circuit through the skin of the mammal between said first hydrogel reservoir and said second hydrogel reservoir using said power source.